The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
Ultra-processed foods, excessive added sugars, and calorie-dense beverages undermine weight maintenance regardless of medication status
American Diabetes Association professional practice committee for diabetes
While rare complications like gastroparesis (stomach paralysis) or pancreatitis can occur, they are uncommon
Key Market Highlights The global GLP-1 analogues market was valued at US$ 51.6 Billion in 2024 The market is expected to reach US$ 211.8 Billion by 2035 The industry is forecast to expand at a CAGR of 13.7% during 2025-2035 North America accounted for the largest market share of 68.4% in 2024 The Subcutaneous route of administration segment held 78.2% market share in 2024 Major industry participants include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and AstraZeneca Rising Type 2 Diabetes Cases Accelerating Market Growth The growing prevalence of type 2 diabetes remains one of the most significant growth drivers for the GLP-1 analogues market
